| Patient | Muhammad Ali |
|---|---|
| Date of birth | 1972-01-17 |
| Identifiers | MRN HR-BX001-SYN; SSN (made up) 000-01-7724 |
| Document date | 2026-11-01 |
| Author | Celeste Moreau, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Establishing primary care for Parkinson's disease: motor, non-motor, fall-risk, and orthostatic assessment. Concerns: He wants to stay steady on his feet and keep making public appearances; People in crowds have trouble hearing him because his voice is soft. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Carbidopa-levodopa 25/100 mg oral tablet, one tablet by mouth three times daily | One tablet by mouth three times daily, at about 7 a.m., noon, and 5 p.m. | Oral route | 2014-10-01 to 2026-03-10 | completed | S |
| Carbidopa-levodopa 25/100 mg oral tablet, one and a half tablets by mouth three times daily, 30 minutes before meals | One and a half tablets (levodopa 150 mg) by mouth three times daily, 30 minutes before meals | Oral route | 2026-03-10 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Speech therapy: four-week intensive voice treatment (LSVT LOUD), 16 sessions | 2026-03-16 to 2026-04-10 | completed | S |
| Advance care planning conversation, about 20 minutes | 2026-10-06 to 2026-10-06 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2025-10-14 | Influenza vaccine, 2025-2026 season | completed | S |
| 2026-10-06 | Influenza vaccine, 2026-2027 season | completed | S |
| 2026-10-06 | Pneumococcal conjugate vaccine PCV20 | completed | S |
| 2026-10-06 | Recombinant zoster vaccine, dose 1 of 2 | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1981 | Professional boxing career with repeated blows to the head, ended by retirement in 1981; whether it caused his Parkinson's disease is disputed | R (CLM-0003, CLM-0006) |
| 1984 | Parkinsonian condition diagnosed in 1984, at 42, by a neurologist in New York, with slowness of movement, a masked face, decreased blinking, tremor, and a shuffling gait | D (CLM-0003, CLM-0004) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| He wants to stay steady on his feet and keep making public appearances | active | S |
| People in crowds have trouble hearing him because his voice is soft | active | S |
Most recent measures: Hemoglobin [Mass/volume] in Blood 14.6 on 2026-02-10; Sodium [Moles/volume] in Serum or Plasma 140 on 2026-02-10; Potassium [Moles/volume] in Serum or Plasma 4.3 on 2026-02-10; Creatinine [Mass/volume] in Serum or Plasma 1.02 on 2026-02-10; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 87 on 2026-02-10; Glucose [Mass/volume] in Serum or Plasma 92 on 2026-02-10; Calcium [Mass/volume] in Serum or Plasma 9.5 on 2026-02-10; Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 512 on 2026-02-10; Thyrotropin [Units/volume] in Serum or Plasma 1.8 on 2026-02-10; Total score [MoCA] 27 on 2026-02-10; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 2026-02-10; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-10-06; Total score [AUDIT-C] 0 on 2026-10-06; Cholesterol [Mass/volume] in Serum or Plasma 192 on 2026-10-06; Cholesterol in HDL [Mass/volume] in Serum or Plasma 50 on 2026-10-06; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 118 on 2026-10-06; Triglyceride [Mass/volume] in Serum or Plasma 120 on 2026-10-06; Hemoglobin A1c/Hemoglobin.total in Blood 5.4 on 2026-10-06 [S]
Strengths and supports: Supports: spouse, adult children, and long-time friends and staff who travel with him [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Parkinson's disease, young onset (diagnosed at 42), Hoehn and Yahr stage 2.5, without dyskinesia or motor fluctuations | active | confirmed | G20.A1 | S — Synthetic modern coding of the publicly disclosed diagnosis; the stage and the absence of motor complications are synthetic. |
| Hypokinetic dysarthria with soft speech due to Parkinson's disease | active | confirmed | R47.1 | S — Synthetic modern coding of the publicly reported speech difficulty; the severity is synthetic. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-02-10 | Hemoglobin [Mass/volume] in Blood | 14.6 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 2026-02-10 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-02-10 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-02-10 | Creatinine [Mass/volume] in Serum or Plasma | 1.02 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-02-10 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 87 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-02-10 | Glucose [Mass/volume] in Serum or Plasma | 92 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-02-10 | Calcium [Mass/volume] in Serum or Plasma | 9.5 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-02-10 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 512 | pg/mL | 232-1245 pg/mL | Normal | S |
| 2026-02-10 | Thyrotropin [Units/volume] in Serum or Plasma | 1.8 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 2026-02-10 | Total score [MoCA] | 27 | {score} | S | ||
| 2026-02-10 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S | ||
| 2026-10-06 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2026-10-06 | Total score [AUDIT-C] | 0 | {score} | S | ||
| 2026-10-06 | Cholesterol [Mass/volume] in Serum or Plasma | 192 | mg/dL | <=200 mg/dL | Normal | S |
| 2026-10-06 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 50 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-10-06 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 118 | mg/dL | <=129 mg/dL | Normal | S |
| 2026-10-06 | Triglyceride [Mass/volume] in Serum or Plasma | 120 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-10-06 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.4 | % | <=5.6% | Normal | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-02-10 | Body height | 191 | cm | S |
| 2026-02-10 | Body weight | 102 | kg | S |
| 2026-02-10 | Body mass index (BMI) [Ratio] | 28 | kg/m2 | S |
| 2026-02-10 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-02-10 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-02-10 | Heart rate | 72 | /min | S |
| 2026-02-10 | Respiratory rate | 14 | /min | S |
| 2026-02-10 | Body temperature | 36.7 | Cel | S |
| 2026-02-10 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-03-10 | Body height | 191 | cm | S |
| 2026-03-10 | Body weight | 102 | kg | S |
| 2026-03-10 | Body mass index (BMI) [Ratio] | 28 | kg/m2 | S |
| 2026-03-10 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-03-10 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-03-10 | Heart rate | 70 | /min | S |
| 2026-03-10 | Respiratory rate | 14 | /min | S |
| 2026-03-10 | Body temperature | 36.6 | Cel | S |
| 2026-03-10 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-06-09 | Body height | 191 | cm | S |
| 2026-06-09 | Body weight | 101.5 | kg | S |
| 2026-06-09 | Body mass index (BMI) [Ratio] | 27.8 | kg/m2 | S |
| 2026-06-09 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-06-09 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-06-09 | Heart rate | 72 | /min | S |
| 2026-06-09 | Respiratory rate | 14 | /min | S |
| 2026-06-09 | Body temperature | 36.7 | Cel | S |
| 2026-06-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-09-08 | Body height | 191 | cm | S |
| 2026-09-08 | Body weight | 101 | kg | S |
| 2026-09-08 | Body mass index (BMI) [Ratio] | 27.7 | kg/m2 | S |
| 2026-09-08 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-09-08 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-09-08 | Heart rate | 70 | /min | S |
| 2026-09-08 | Respiratory rate | 14 | /min | S |
| 2026-09-08 | Body temperature | 36.6 | Cel | S |
| 2026-09-08 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-10-06 | Body height | 191 | cm | S |
| 2026-10-06 | Body weight | 101.2 | kg | S |
| 2026-10-06 | Body mass index (BMI) [Ratio] | 27.7 | kg/m2 | S |
| 2026-10-06 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-10-06 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-10-06 | Heart rate | 70 | /min | S |
| 2026-10-06 | Respiratory rate | 14 | /min | S |
| 2026-10-06 | Body temperature | 36.7 | Cel | S |
| 2026-10-06 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-02-10 | Establishing primary care for Parkinson's disease: motor, non-motor, fall-risk, and orthostatic assessment | finished | S |
| 2026-03-10 | Four-week follow-up with movement disorders neurology consultation for levodopa adjustment and rehabilitation | finished | S |
| 2026-06-09 | Three-month Parkinson's disease review after the levodopa increase and speech therapy | finished | S |
| 2026-09-08 | Six-month Parkinson's disease review | finished | S |
| 2026-10-06 | Periodic adult preventive visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Review the levodopa dose and timing at every visit for slowness, wearing-off, and dyskinesia; take doses 30 minutes before meals; check supine and three-minute standing blood pressure after any change; avoid dopamine-blocking drugs such as metoclopramide, prochlorperazine, and most antipsychotics | completed | GL-AAN-PD-2021, GL-AAS-OH-2017, GL-CMID-2026 | S |
| Movement disorders neurology consultation to confirm the diagnosis against the MDS criteria, adjust levodopa, plan rehabilitation, and advise on genetic testing | completed | GL-MDS-CRIT-2015, GL-AAN-PD-2021, GL-CMID-2026 | S |
| Four-week intensive speech therapy (LSVT LOUD) for soft speech, and physical therapy for gait, balance, and a home exercise program of at least 150 minutes a week | completed | GL-CMID-2026 | S |
| Monitor on the CMID schedule: motor examination, Hoehn and Yahr stage, fall check, psychosis and impulse-control questions, and medication review every visit; cognition, mood, sleep, autonomic symptoms, swallowing, speech, and driving yearly; dental examination every six months | completed | GL-CMID-2026, GL-MDS-CRIT-2015 | S |
| Advance care planning: name a health care agent and record goals of care, and revisit with any change in stage | completed | GL-CMID-2026 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Less slowness of movement after a levodopa adjustment, without dyskinesia or orthostatic hypotension, by the three-month review | 2026-06-09 | completed | MDS-UPDRS Part III fell from 30 to 24; no dyskinesia; no orthostatic hypotension | S |
| Complete a four-week intensive speech therapy course and keep up daily voice practice | 2026-06-09 | completed | LSVT LOUD course completed; easier to hear in conversation; daily home practice continues | S |
| No falls through the six-month review, with at least 150 minutes a week of exercise including balance work | 2026-09-08 | completed | No falls; Timed Up and Go improved from 13 to 11 seconds; exercising about 180 minutes a week | S |
| Name a health care agent and record his goals of care by the preventive visit | 2026-10-06 | completed | Health care agent named and goals of care recorded at the preventive visit | S |